REMARKS

The specification, claims, and abstract have been amended to correct typographical errors and to correctly refer to familial autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE). No new matter has been added by the present amendment. In addition, applicants have updated the priority information. Support for this amendment is found in the Utility Patent Application Transmittal under 37 C.F.R. § 1.53(b).

The claims have also been amended to conform with 37 C.F.R. § 1.75.

Enclosed is an executed Statement of Accuracy of Translation declaring that the translation of the above-referenced application is accurate.

If there are any additional charges or any credits, please apply them to Deposit Account No. 03-2095.

Date: May 4, 2004

Clark & Elbing LLP 101 Federal Street Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045

Respectfully submitted,

Kristina Bieker-Brady, Ph

Reg. No. 39,109